ClariVest Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

ClariVest Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,060	Closed	-$719K	–	784
2023 Q1	$719K	Sell	31,060 -124	-0.4%	-$2.96K	0.03%	329
2022 Q4	$817K	Sell	31,184 -413	-1%	-$9.15K	0.04%	305
2022 Q3	$621K	Buy	31,597 +41	+0.1%	+$822	0.03%	329
2022 Q2	$552K	Buy	+31,556	New	+$495K	0.02%	363
2022 Q1	–	Sell	-52,657	Closed	-$859K	–	798
2021 Q4	$859K	Sell	52,657 -900	-2%	-$12.8K	0.03%	348
2021 Q3	$684K	Sell	53,557 -300	-0.6%	-$3.95K	0.02%	382
2021 Q2	$761K	Buy	+53,857	New	+$861K	0.03%	351

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClariVest Asset Management's KDNY Position: Q2 2023 in Review

ClariVest Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 31,060 shares — an estimated $719K sold.

ClariVest Asset Management first reported a position in KDNY in Q2 2021 and held it in 7 quarters. The position peaked at $859K in Q4 2021. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

ClariVest Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
ClariVest Asset Management sold 31,060 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $719K.
ClariVest Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
ClariVest Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $859K in Q4 2021.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on ClariVest Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.